Home Cart Sign in  
Chemical Structure| 33342-05-1 Chemical Structure| 33342-05-1

Structure of Gliquidone
CAS No.: 33342-05-1

Chemical Structure| 33342-05-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Gliquidone is an ATP-sensitive K+ channel antagonist with IC50 of 27.2 nM.

Synonyms: AR-DF 26

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Gliquidone

CAS No. :33342-05-1
Formula : C27H33N3O6S
M.W : 527.63
SMILES Code : O=S(C1=CC=C(CCN(C(C(C)(C)C2=C3C=C(OC)C=C2)=O)C3=O)C=C1)(NC(NC4CCCCC4)=O)=O
Synonyms :
AR-DF 26
MDL No. :MFCD00631870
InChI Key :LLJFMFZYVVLQKT-UHFFFAOYSA-N
Pubchem ID :91610

Safety of Gliquidone

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • Potassium Channel

    Potassium channel, IC50:27.2 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Human foreskin fibroblasts 1 (HFF-1) 7.6 µM 5 days Evaluation of Gliquidone's inhibitory effect on in vitro infection by T. cruzi Querétaro strain, IC50 of 7.6 µM PMC11768481
Cos7 cells 1, 10, 30, 100 μM 24 hours To evaluate the effect of gliquidone on PPARγ transcriptional activity. Results showed that gliquidone exhibited PPARγ agonistic activity at 1 μM, increased activity by 3-4 times at 10 μM, and nearly ten times at higher concentrations. PMC3178694
Primary astrocytes 5 μM 5.5 h or 23.5 h Gliquidone selectively affected LPS-mediated proinflammatory cytokine expression and decreased STAT3/NF-κB signaling in an NLRP3-independent manner. PMC8587901
BV2 microglial cells 5 μM 5.5 h or 23.5 h Gliquidone significantly decreased LPS-induced proinflammatory cytokine levels and inhibited ERK/STAT3/NF-κB phosphorylation by altering NLRP3 inflammasome activation. PMC8587901
CA3 hippocampal neurons 10μM Gliquidone significantly depressed the slowly inactivating outward current (ID) by 42·6±7·9% (n=13). PMC1175465

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Tail flick test model Intracerebroventricular injection 0.06-16 μg/mouse Single injection, observed for 120 minutes To evaluate the effects of gliquidone on the antinociception induced by different μ-opioid receptor agonists. Results showed that gliquidone antagonized the antinociception induced by buprenorphine, morphine, and methadone but did not affect the effects of fentanyl and levorphanol. PMC1510369
Swiss albino mice Forced swimming test Intracerebroventricular injection 6 mg/mouse Single dose, 20 min before the test To evaluate the effect of gliquidone on immobility time in mice, results showed that gliquidone significantly reduced immobility time, comparable to tricyclic antidepressants. PMC1565937
Mice Tail flick test Intracerebroventricular injection 4-8 μg/mouse Single administration Gliquidone significantly antagonized clonidine-induced antinociception but did not significantly modify baclofen-induced antinociception. PMC2175792
Swiss albino mice Hot-plate test model Intracerebroventricular injection 6 mg/mouse Single injection, 15 minutes before the test Gliquidone, by blocking K ATP channels, prevented the antinociception induced by the α2-adrenoceptor agonists clonidine and guanabenz. PMC1565873
C57BL6/N mice Neuroinflammatory disease model Intraperitoneal injection 10 or 20 mg/kg Daily injections for 3 consecutive days Gliquidone suppressed LPS-mediated microgliosis, microglial hypertrophy, and proinflammatory cytokine COX-2 and IL-6 levels in wild-type mice, with smaller effects on astrogliosis. Importantly, gliquidone downregulated the LPS-induced microglial NLRP3 inflammasome and peripheral inflammation in wild-type mice. PMC8587901
Swiss albino mice Passive avoidance test model Intracerebroventricular injection 3 mg/mouse Single dose 20 min before training Prevented potassium channel opener-induced amnesia PMC1565263

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02476760 - Completed - Canada, Quebec ... More >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Less <<
NCT02475499 - Completed - Canada, Quebec ... More >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Less <<
NCT00568074 Diabetes Diab... More >>etes Mellitus, Type 2 Less << Phase 4 Completed - China, Shanghai ... More >> Novo Nordisk Investigational Site Shanghai, Shanghai, China, 200025 Novo Nordisk Investigational Site Shanghai, Shanghai, China, 200433 China, Sichuan Novo Nordisk Investigational Site Chengdu, Sichuan, China, 610041 China Novo Nordisk Investigational Site Beijing, China, 100029 Less <<
NCT02456428 - Completed - Canada, Quebec ... More >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Less <<
NCT01413035 Type 2 Diabetes Phase 1 Phase 2 Unknown July 2014 China, Shandong ... More >> Department of Hematology of the 2nd Hospital of Shandong University Recruiting Jinan, Shandong, China, 250033 Contact: chengyun zheng, Ph. D    +86-531-85875635    chengyun.zheng@ki.se, kdx2002@126.com Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.90mL

0.38mL

0.19mL

9.48mL

1.90mL

0.95mL

18.95mL

3.79mL

1.90mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories